Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Paul E. Andrews is active.

Publication


Featured researches published by Paul E. Andrews.


The Journal of Urology | 1995

PROSPECTIVE ANALYSIS OF MULTIFOCALITY IN RENAL CELL CARCINOMA: INFLUENCE OF HISTOLOGICAL PATTERN, GRADE, NUMBER, SIZE, VOLUME AND DEOXYRIBONUCLEIC ACID PLOIDY

Bruce A. Kletscher; Junqi Qian; David G. Bostwick; Paul E. Andrews; Horst Zincke

In an effort to characterize more fully multifocal renal cell carcinoma, 100 radical nephrectomy specimens with localized renal cell carcinoma were analyzed in a prospective fashion. Analysis of each specimen consisted of preoperative computerized tomography or magnetic resonance imaging, standard pathological examination with frozen section and 3 mm. step sectioning under magnification. Multifocal renal cell carcinoma was found in 16 specimens. Multifocal disease was suspected by preoperative imaging in 7 specimens (44%) and confirmed after standard pathological investigation in 10 (63%). Papillary and mixed histological patterns occurred at a significantly increased rate in specimens with multifocal disease (p = 0.011). Other parameters, such as stage, tumor size and volume, histological grade and deoxyribonucleic acid ploidy were evaluated and did not correlate with the presence or extent of multifocality. The number of secondary tumors per specimen varied from 1 to 50 (median 2) and were of higher grade in 3 (19%) and of lower grade in 2 (12%) when compared with the predominant tumor. In conclusion, information from preoperative and to some degree intraoperative tests (except histological pattern) cannot reliably predict multifocality. The true risk for unknown multifocality in a surgical setting seems to be 6%, which roughly corresponds to the incidence of locally recurrent disease in published large institutional series.


European Urology | 2010

The Learning Curve of Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium

Matthew H. Hayn; Abid Hussain; Ahmed M. Mansour; Paul E. Andrews; Paul Carpentier; Erik P. Castle; Prokar Dasgupta; Peter Rimington; Raju Thomas; Shamim Khan; Adam S. Kibel; Hyung L. Kim; Murugesan Manoharan; Mani Menon; Alex Mottrie; David K. Ornstein; James O. Peabody; Raj S. Pruthi; Joan Palou Redorta; Lee Richstone; Francis Schanne; Hans Stricker; Peter Wiklund; Rameela Chandrasekhar; G. Wilding; Khurshid A. Guru

BACKGROUND Robot-assisted radical cystectomy (RARC) has evolved as a minimally invasive alternative to open radical cystectomy for patients with invasive bladder cancer. OBJECTIVE We sought to define the learning curve for RARC by evaluating results from a multicenter, contemporary, consecutive series of patients who underwent this procedure. DESIGN, SETTING, AND PARTICIPANTS Utilizing the International Robotic Cystectomy Consortium database, a prospectively maintained and institutional review board-approved database, we identified 496 patients who underwent RARC by 21 surgeons at 14 institutions from 2003 to 2009. MEASUREMENTS Cut-off points for operative time, lymph node yield (LNY), estimated blood loss (EBL), and margin positivity were identified. Using specifically designed statistical mixed models, we were able to inversely predict the number of patients required for an institution to reach the predetermined cut-off points. RESULTS AND LIMITATIONS Mean operative time was 386 min, mean EBL was 408 ml, and mean LNY was 18. Overall, 34 of 482 patients (7%) had a positive surgical margin (PSM). Using statistical models, it was estimated that 21 patients were required for operative time to reach 6.5h and 8, 20, and 30 patients were required to reach an LNY of 12, 16, and 20, respectively. For all patients, PSM rates of <5% were achieved after 30 patients. For patients with pathologic stage higher than T2, PSM rates of <15% were achieved after 24 patients. CONCLUSIONS RARC is a challenging procedure but is a technique that is reproducible throughout multiple centers. This report helps to define the learning curve for RARC and demonstrates an acceptable level of proficiency by the 30th case for proxy measures of RARC quality.


The Journal of Urology | 2010

Surgical Margin Status After Robot Assisted Radical Cystectomy: Results From the International Robotic Cystectomy Consortium

Nicholas J. Hellenthal; Abid Hussain; Paul E. Andrews; Paul Carpentier; Erik P. Castle; Prokar Dasgupta; Jihad H. Kaouk; Shamim Khan; Adam S. Kibel; Hyung L. Kim; Murugesan Manoharan; Mani Menon; Alex Mottrie; David K. Ornstein; Joan Palou; James O. Peabody; Raj S. Pruthi; Lee Richstone; Francis Schanne; Hans Stricker; Raju Thomas; Peter Wiklund; G. Wilding; Khurshid A. Guru

PURPOSE Positive surgical margins at radical cystectomy confer a poor prognosis. We evaluated the incidence and predictors of positive surgical margins in patients who underwent robot assisted radical cystectomy for bladder cancer. MATERIALS AND METHODS Using the International Robotic Cystectomy Consortium database we identified 513 patients who underwent robot assisted radical cystectomy, as done by a total of 22 surgeons at 15 institutions from 2003 to 2009. After stratification by age group, gender, pathological T stage, nodal status, sequential case number and institutional volume logistic regression was used to correlate variables with the likelihood of a positive surgical margin. RESULTS Of the 513 patients 35 (6.8%) had a positive surgical margin. Increasing 10-year age group, lymph node positivity and higher pathological T stage were significantly associated with an increased likelihood of a positive margin (p = 0.010, <0.001 and p <0.001, respectively). Gender, sequential case number and institutional volume were not significantly associated with margin positivity. The rate of margin positive disease at cystectomy was 1.5% for pT2 or less, 8.8% for pT3 and 39% for pT4 disease. CONCLUSIONS Positive surgical margin rates at robot assisted radical cystectomy for advanced bladder cancer were similar to those in open cystectomy series in a large, multi-institutional, prospective cohort. Sequential case number, a surrogate for the learning curve and institutional volume were not significantly associated with positive margins at robot assisted radical cystectomy.


The Journal of Urology | 1993

Preoperative Androgen Deprivation Therapy: Artificial Lowering of Serum Prostate Specific Antigen without Downstaging the Tumor

Joseph E. Oesterling; Paul E. Andrews; Vera J. Suman; Horst Zincke; Robert P. Myers

We studied 22 patients with clinical stage B2 (T2c) or C (T3) prostate cancer who underwent androgen deprivation therapy before radical prostatectomy as part of a downstaging protocol (group 1). The concentration of serum prostate specific antigen (PSA) was determined before and at the conclusion of androgen deprivation therapy, just before the operation. For each group 1 patient a match patient who had not received preoperative endocrine therapy (group 2) was chosen. The age of the group 2 patients was similar to that of the group 1 patients. The clinical stage of disease and pretreatment tumor grade in group 2 were identical to the stage and grade in group 1, and the serum PSA value in group 2 was similar to that of group 1 before initiation of androgen deprivation therapy. In group 1 the median serum PSA concentration was 14.8 ng./ml. (range 3.1 to 99) before endocrine therapy and 0.2 ng./ml. (range 0.1 to 3.4) after hormonal treatment. Group 2 had a median level of 13.3 ng./ml. (range 3.4 to 100). The median decrease in the serum PSA concentration for group 1 as a result of androgen deprivation therapy was 98.5%. The radical prostatectomy specimens from these 2 groups of similar patients had no difference with regard to maximal tumor dimension, pathological stage and deoxyribonucleic acid ploidy status. These findings indicate that serum PSA becomes an unreliable indicator of disease status after initiating preoperative androgen deprivation therapy and that preoperative androgen deprivation therapy has little or no benefit for decreasing the extent of tumor or pathological stage. The concept of downstaging is misleading and must be examined in a randomized clinical trial.


BJUI | 2008

Bilateral laparoscopic nephrectomy for significantly enlarged polycystic kidneys: a technique to optimize outcome in the largest of specimens

Premal J. Desai; Erik P. Castle; Shane M. Daley; Scott K. Swanson; Robert G. Ferrigni; Mitchell R. Humphreys; Paul E. Andrews

To present our experience with bilateral laparoscopic nephrectomy (BLN) for symptomatic autosomal‐dominant polycystic kidney disease (ADPKD), as surgical management of massively enlarged polycystic kidneys can be a daunting task.


BJUI | 2011

Lymphadenectomy at the time of robot‐assisted radical cystectomy: results from the International Robotic Cystectomy Consortium

Nicholas J. Hellenthal; Abid Hussain; Paul E. Andrews; Paul Carpentier; Erik P. Castle; Prokar Dasgupta; Jihad H. Kaouk; Shamim Khan; Adam S. Kibel; Hyung L. Kim; Murugesan Manoharan; Mani Menon; Alex Mottrie; David K. Ornstein; Joan Palou; James O. Peabody; Raj S. Pruthi; Lee Richstone; Francis Schanne; Hans Stricker; Raju Thomas; Peter Wiklund; G. Wilding; Khurshid A. Guru

What’s known on the subject? and What does the study add?


Journal of Endourology | 2008

Outcomes of laparoscopic radical nephrectomy in the setting of vena caval and renal vein thrombus: Seven-year experience

George L. Martin; Erik P. Castle; Aaron D. Martin; Premal J. Desai; Robert G. Ferrigni; Paul E. Andrews

PURPOSE We present our experience with laparoscopic radical nephrectomy for T(3b) disease focusing on thrombus within the vena cava. PATIENTS AND METHODS A total of 14 patients with T(3b) disease were identified from a retrospective laparoscopic renal cancer database from 2000 to 2007. Patient demographics, clinical stage, preoperative imaging, intraoperative parameters, final pathology, and postoperative course were analyzed. In patients with a large tumor thrombus, the infraumbilical extraction excision was performed early and a gel port was placed. This was used when laparoscopic milking or determination of the distal extent of the tumor thrombus was difficult. RESULTS Preoperative imaging identified T(3b) disease in all but four patients. Four patients had caval involvement seen on imaging, with one extending well above 2 to 3 cm above the renal vein. Of the 14 patients, procedures in 13 were completed laparoscopically. There was one conversion early in the experience because of a positive frozen section of the renal vein; however, additional vein and caval margins were negative. There was one complication-a pulmonary embolism 5 days postoperatively, managed with anticoagulation, with no disease recurrence 4 years later. CONCLUSION In patients with T(3b) disease, laparoscopy is feasible and safe. Using advanced laparoscopic techniques to milk the tumor thrombus into the proximal renal vein with laparoscopic vascular instruments is critical to success in a purely laparoscopic thrombectomy. Placement of a gel port in the extraction incision early in the procedure may aid in hand-milking of the tumor thrombus into the renal vein in cases of extensive inferior vena cava involvement.


Journal of Endourology | 2008

Robot-assisted extended pelvic lymphadenectomy.

Michael Woods; Raju Thomas; Rodney Davis; Paul E. Andrews; Robert G. Ferrigni; Joan Cheng; Eric P. Castle

PURPOSE To evaluate perioperative and pathologic outcomes of patients undergoing robot-assisted extended pelvic lymphadenectomy for bladder cancer. MATERIALS AND METHODS A retrospective chart review was performed for all 27 patients who underwent robotassisted radical cystectomy (RARC) and extended pelvic lymphadenectomy at Tulane University and Mayo Clinic Arizona between March 2005 and April 2007. Baseline demographic, perioperative, and pathologic data were evaluated. The bifurcation of the aorta was the proximal border of dissection in all patients. RESULTS There was a total of 27 patients, and all procedures were completed laparoscopically; all urinary diversions were constructed extracorporeally in RARC patients. The mean total operative time was 400 minutes, and mean blood loss was 277 mL. All patients had transitional-cell carcinoma in the bladder cancer group. The mean total lymph node count for the RARC group was 12.3 (range 7-20). There were no intraoperative complications, and 9 (33%) patients experienced postoperative complications. CONCLUSIONS An extended pelvic lymphadenectomy can be reliably and safely performed robotically during RARC in the management of bladder cancer. The robotic system aids in performing a meticulous dissection and in adhering to sound oncologic principles.


BJUI | 2009

Robot-assisted radical cystectomy: Intermediate survival results at a mean follow-up of 25 months

Aaron D. Martin; Rafael N. Nunez; Anna Pacelli; Michael Woods; Rodney Davis; Raju Thomas; Paul E. Andrews; Erik P. Castle

Study Type – Therapy (case series)
Level of Evidence 4


BJUI | 2015

Robot-assisted retroperitoneal lymph node dissection: technique and initial case series of 18 patients

Scott M. Cheney; Paul E. Andrews; Bradley C. Leibovich; Erik P. Castle

To evaluate outcomes of the first 18 patients treated with robot‐assisted retroperitoneal lymph node dissection (RA‐RPLND) for non‐seminomatous germ cell tumours (NSGCT) and paratesticular rhabdomyosarcoma (RMS) at our institution.

Collaboration


Dive into the Paul E. Andrews's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mark D. Tyson

Vanderbilt University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Abid Hussain

Roswell Park Cancer Institute

View shared research outputs
Researchain Logo
Decentralizing Knowledge